CannTrust (TSX:TRST) Busted Again: Avoid it Like the Plague

CannTrust Holdings Inc. (TSX:TRST)(NYSE:CTST) is in hot water again. You should avoid it like the plague.

Red siren flashing

Image source: Getty Images.

After Aphria announced its financial earnings for the 2019 fiscal year this month, you might have been curious about the performance of CannTrust (TSX:TRST)(NYSE:CTST). Unfortunately, you will be bitterly disappointed by the company after it started to face problems with regulators and its stock plummeted.

What happened with CannTrust?

The dominoes began to fall when CannTrust applied for a management cease trade order on August 1, 2019. The company did so because it seemed likely that it would not be possible to file interim financial reports by the August 14th deadline. CannTrust was responding to a health inspection carried out by Health Canada between July 10 and July 16 this year.

Health Canada would come to rate the company’s facility in Vaughan, Ontario, as non-compliant. The July inspection by Health Canada revealed that its facility was using five rooms for storage that were previously used for operations. CannTrust was also constructing two new areas for storage.

The company had neither sought approval for these new constructions nor the re-purposing of operational areas for storage. That was in addition to more non-compliance issues found in its greenhouse facility in Pelham, Ontario, previously.

Health Canada thus placed a hold on 5,200 kg of cannabis harvested in Pelham and CannTrust voluntarily placed a hold on an additional 7,500 kg from Vaughan.

To add to the company’s woes, its auditor, KPMG, withdrew its endorsement of CannTrust financial statements for the 2018 fiscal year. In a statement, KPMG stated that the financial documents by the company should not be relied upon after a special committee uncovered new information.

What does all of this mean for CannTrust?

The most obvious impact from all the above mishaps has been to the company’s stock. Since Health Canada first reported non-compliance at CannTrust facilities in July, the company’s stock has dropped by more than 60%.

With the withdrawal of KPMG, there is no reliable information on the company’s latest financials even though trading is still ongoing. By applying for a management cease trade order from the Ontario Securities Commission, the order only prohibits management, directors, and other insiders from trading the company’s stock.

You are still free to trade as usual both on the TSX and NYSE. The NYSE noted that failing to file its 2018 annual report by the August 14th deadline might lead to a halting of trade after six months.

Should investors be worried?

One of the biggest problems to consider is that this isn’t the first time CannTrust have been found violating the law. The special committee investigating circumstances surrounding the non-compliance findings by Health Canada discovered a lot of new information.

There are uncovered emails that revealed management’s knowledge of the illegal grows in the company’s facilities, and that the company had nevertheless exported the product. This led to the removal of CEO Peter Aceto and Chairman Eric Paul on July 25.

Another problem you must keep in mind is the company’s financials. In March, CannTrust reported a net loss of $25.5 million for the fourth quarter of 2018 fiscal year. Many institutional investors were hoping that the company would be edging closer to profitability, but instead, the company reported a much higher loss than anticipated.

Remember, this was despite recreational marijuana being legalized in the fourth quarter of 2018. Worse still, the company was planning to spend even more on acquiring new land, about 200 acres, for outdoor growing.

In conclusion

For these reasons, CannTrust seems to be an unfavorable investment, and short-sellers are increasing their bets. The latest regulatory troubles only exacerbate the problems for the company, making it a strong sell for speculators and a no-go for you.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned.

More on Cannabis Stocks

Pot stocks are a riskier investment
Cannabis Stocks

Is the Worst Over for Canopy Growth Stock?

Down 99% from all-time highs Canopy Growth stock has burnt investor wealth and remains a high-risk investment.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Steer Clear: This Stock Spells Trouble

A newly listed cannabis stock is outperforming in 2024 but investors should stay clear to avoid trouble and losses.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

2 Best Marijuana Stocks to Buy This Month

Marijuana stocks in the U.S. such as Green Thumb and Curaleaf can help you deliver outsized gains to investors in…

Read more »

A cannabis plant grows.
Cannabis Stocks

Can Aurora Cannabis Stock Recover in 2024?

Aurora Cannabis stock is down 99% from all-time highs but remains a high-risk bet, despite its cheap valuation.

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

The Best Cannabis Stock to Buy Right Now

This cannabis stock has jumped 30% in the last few months, with even more growth on the way – all…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Down 99% From All-Time Highs, Is Canopy Growth Stock a Good Buy Right Now?

Canopy Growth stock is a high-risk investment due to its negative profit margins and challenging liquidity position.

Read more »

Marijuana plant and cannabis oil bottles isolated
Stocks for Beginners

Aurora Cannabis’ Reverse Stock Split: Is the Stock a Buy Today?

Cannabis stock Aurora (TSX:ACB) is consolidating shares once again, but what does this mean for investors?

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Where Will Cannabis Stocks Be in 10 Years?

Cannabis stocks could see a huge shift upwards should marijuana be rescheduled in the U.S., but you can still buy…

Read more »